RAD June 2024 Abstracts and Posters
652 Tralokinumab real-world use in adults with atopic dermatitis: baseline characteristics of the first 100 patients recruited to the TRACE study in the United States
April W. Armstrong, Cory Rubin, Abel Jarell, Tien Nguyen, Jerry Bagel, John Stinson, Shannon Schneider, Dimitra M. Anastasiadou, Adrian Rodriguez
653 Efficacy and safety of delgocitinib cream in adults with moderate to severe chronic hand eczema: pooled results of the phase 3 DELTA-1 and -2 trials
Robert Bissonnette, Margitta Worm, Richard B Warren, Tove Agner, Melinda Gooderham, Marie Louise Schuttelaar, Keith Baranowski, Ursula Plohberger, Laura Soerensen, Sibylle Schliemann
654 Delgocitinib cream reduces itch and pain in adults with moderate to severe chronic hand eczema: pooled analyses of the 0hase 3 DELTA-1 and -2 trials
Andrea Bauer, Marie-Louise Schuttelaar, Keith Baranowski, Ursula Plohberger, Laura Sørensen, Margitta Worm
655 Long-term safety and efficacy of delgocitinib cream for up to 36 weeks in adults with chronic hand eczema: results of the phase 3 open-label extension DELTA-3 trial
Melinda Gooderham, Sonja Molin, Robert Bissonnette, Margitta Worm, Marie-Noëlle Crépy, Luca Stingeni, Richard B Warren, Sibylle Schliemann, Cherry Lou Balita-Crisostomo, Marie Louise Oesterdal, Tove Agner
656 Systemic exposure and safety profile of delgocitinib cream in adults with moderate to severe chronic hand eczema in the phase 3 DELTA-2 trial
Melinda Gooderham, Diamant Thaçi, Tina Damgaard, Daniel Madsen, Anders Soehoel, Robert Bissonnette
657 Impact of pruritus on patient fatigue: a case-control study
Luis F. Andrade, BSc; Zaim Haq, BA; Parsa Abdi, BASc; Michael J. Diaz, BS; Gil Yosipovitch, M
658 IMG-007, a novel nondepleting anti-OX40 monoclonal antibody with Fc bioengineering, exhibited reduced safety risks: evidence from nonclinical studies
Chongtian Guo, Xiaotong Wu, Zi Lin, Yufang Lu
659 Positive patient-reported outcomes following treatment of stable vitiligo with autologous skin cell suspension transplantation prepared by a point-of-care cell harvesting device
Nanette B. Silverberg, MD and the RSVP Study Vitiligo Working Group
661 Efficacy and safety of amlitelimab, an anti-OX40 ligand antibody, in patients with moderate-to-severe atopic dermatitis (AD): a phase 2b trial (STREAM-AD)
Stephan Weidinger; Andrew Blauvelt; Kim Papp; Adam Reich; Chih-Hung Lee; Margitta Worm; Charles Lynde; Yoko Kataoka; Peter Foley; Christine Weber; Anne-Catherine Solente; Samuel Adelman; Sonya Davey; Wanling Wong; Natalie Rynkiewicz; Karl Yen; John T. O’Malley; Charlotte Bernigaud
665 Lack of publications assessing patient impact of vitiligo and alopecia areata
Sarah Brown, Emily Chastain, Kaylen Suryajaya, Sarah Feaver, and Stephanie Harbers